Immunovant FY27 Q1 net loss widens 27% to $153.2 million; R&D expenses rise 40.9% to $142.6 million
IMVT•Cash position and program timelines
Cash and cash equivalents totaled $797.8 million as of June 30, 2026, providing runway to a potential commercial launch of IMVT-1402 in Graves' disease.
IMVT-1402 timelines stayed on track; CLE topline data are expected in 2H 2026, with GD and MG topline data anticipated in 2027.
Quarterly loss widens as R&D spending rises
Immunovant posted a wider net loss of $153.2 million, or $0.75 a share, for the quarter ended June 30, 2026.
R&D expense rose 40.91% to $142.6 million, due to IMVT-1402 trial activity including contract manufacturing costs, partly offset by lower batoclimab wind-down costs.
G&A expense fell 31.92% to on lower personnel-related costs, professional fees, market research, and IT spending.
